Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 9/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.44 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7471234 | 1.00 | TRPC6 (0.52) | TRPC6KDM4ETP53KDM1AHRH3 | |
| SCHEMBL7466319 | 0.95 | TRPC6 (0.48) | TRPC6KDM4ETP53KDM1AHRH3 | |
| SCHEMBL1238920 | 0.90 | KDM4E (0.50) | TRPC6KDM4ETP53KDM1AHRH3 | |
| SCHEMBL31720517 | 0.83 | KDM4E (0.52) | TRPC6KDM4ETP53HRH3CHRNA10 | |
| SCHEMBL6501263 | 0.82 | NOTUM (0.56) | LRRK2PRKCQMAP4K1 | |
| SCHEMBL6496702 | 0.82 | NOTUM (0.56) | LRRK2PRKCQMAP4K1 | |
| SCHEMBL14637983 | 0.81 | AR (0.50) | KDM4ETP53HRH3CHRNA10CHRNA9 | |
| SCHEMBL1238733 | 0.80 | KDM4E (0.58) | KDM4ETP53KDM1AHRH3CHRNA10 | |
| SCHEMBL25431296 | 0.79 | PIM1 (0.48) | TRPC6 | |
| SCHEMBL30542820 | 0.79 | PIM1 (0.48) | TRPC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1250935-A1 | REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| EP-1227083-A1 | 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN $g(a)v$g(b)3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040531-A1 | Remedies for reperfusion injury containing integrin alphanubeta 3 antagonist | ITGB3, ITGAV, ITGB1 | TRPC6 458/4885KDM4E 4216/4885TP53 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.